Torsten Falk

Has grant

Associate Professor

University of Arizona

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Torsten Falk is an Associate Professor at the University of Arizona, USA. His research focuses on the neuropharmacology of movement disorders, specifically Parkinson's disease, and explores the therapeutic potentials of various compounds, including sub-anesthetic ketamine and glycopeptides. Recent publications highlight his investigations into cognitive enhancement, neuroinflammation modulation, and the effects of opioid receptor interactions in preclinical models.

Recent Grants

Grant: Close

Mechanisms of Low-Dose Ketamine Treatment for Parkinson's Disease

Open Date: 2021-07-01

Close Date: 2025-06-30

Grant: Close

Mechanisms of low-dose ketamine treatment for Parkinson's disease

Open Date: 2019-09-15

Close Date: 2021-06-30

Articles (17)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (4)

Jean Bidlack

Professor

University of Rochester School of Medicine and Dentistry

UNITED STATES

View details

Kristian Doyle

Associate Professor

University of Arizona

UNITED STATES

View details

James Siegenthaler

Adjunct Research Professor

Michigan State University

UNITED STATES

View details

Robin Polt

Professor

University of Arizona

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Torsten Falk

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (17)

Decoupling of motor cortex to movement in Parkinson's dyskinesia rescued by sub-anaesthetic ketamine.

Differential effects of statins on the anti-dyskinetic activity of sub-anesthetic ketamine.

Cyclic Glycopeptide Analogs of Endomorphin-1 Provide Highly Effective Antinociception in Male and Female Mice.

The angiotensin (1-7) glycopeptide PNA5 improves cognition in a chronic progressive mouse model of Parkinson's disease through modulation of neuroinflammation.

PACAP glycosides promote cell outgrowth in vitro and reduce infarct size after stroke in a preclinical model.

Differential effects of opioid receptor antagonism on the anti-dyskinetic and anti-parkinsonian effects of sub-anesthetic ketamine treatment in a preclinical model.

Structure-Based Design of Glycosylated Oxytocin Analogues with Improved Selectivity and Antinociceptive Activity.

Automated system for training and assessing reaching and grasping behaviors in rodents.

Antagonism of kappa opioid receptors accelerates the development of L-DOPA-induced dyskinesia in a preclinical model of moderate dopamine depletion.

Design and Synthesis of Brain Penetrant Glycopeptide Analogues of PACAP With Neuroprotective Potential for Traumatic Brain Injury and Parkinsonism.

Spectral signatures of L-DOPA-induced dyskinesia depend on L-DOPA dose and are suppressed by ketamine.

Can quantifying morphology and TMEM119 expression distinguish between microglia and infiltrating macrophages after ischemic stroke and reperfusion in male and female mice?

Evaluation of microglia in a rodent model of Parkinson's disease primed with L-DOPA after sub-anesthetic ketamine treatment

The Delta-Specific Opioid Glycopeptide BBI-11008: CNS Penetration and Behavioral Analysis in a Preclinical Model of Levodopa-Induced Dyskinesia

Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia.

Sleep Spindles and Fragmented Sleep as Prodromal Markers in a Preclinical Model of LRRK2-G2019S Parkinson's Disease.

Highly-selective µ-opioid receptor antagonism does not block L-DOPA-induced dyskinesia in a rodent model.

Collaborators (4)

Jean Bidlack

Kristian Doyle

James Siegenthaler

Robin Polt

Make your next move.